secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-097036
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q2 2024 revenue $140K, net loss $1.3M; Phase 1 VNS results, cost cuts
--------------------------------------------------------------------------------

- Q2 2024 revenue $140K vs $203K in Q2 2023; H1 2024 revenue $474K, down 12% YoY.
- Net loss Q2 2024 $1.3M vs $2.1M; H1 net loss $2.7M, $1.5M improvement from H1 2023.
- Gross margin improved to 42% in H1 2024 from 32% in H1 2023 due to cost reductions.
- Cash and equivalents $3.7M as of June 30, 2024; raised $3.3M net from May 2024 offering.
- Phase 1 VNS trial results with Feinstein Institutes; ClearUP 2.0 launched; lease and logistics savings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024097036/0000950170-24-097036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024097036/tivc-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-097036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer